Study: Inflammatory cells in tumor microenvironment transform prostate cancer cells into treatment-resistant cells

Treatment-resistant cells are a challenge related to prostate cancer and many other cancers, which arises as the disease progresses. However, these resistance mechanisms are not yet fully understood. A new study by the University of Eastern Finland found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus make them immune to treatment.

The results are published in OncoImmunology . The study examined the impact of factors promoting inflammation in a tumor microenvironment on the progression of prostate cancer. Researchers focused particularly on the role of M1 and M2 macrophages in the tumor microenvironment.



Macrophages are immune cells whose large number in the tumor area is often a sign of poor prognosis in relation to prostate cancer. The study found that pro-inflammatory macrophages (M1) increase the stem cell traits of cancer cells and weaken the androgen response. "We found that pro-inflammatory M1 macrophages secreted factors that increased the expression of stem cell markers such as NANOG, KLF4, SOX2 and CD44 in prostate cancer cells.

Based on our research, it seems that the inflammatory tumor microenvironment promotes the transformation of prostate cancer cells into a stem cell-like state where they are resistant to traditional therapies," says Doctoral Researcher Kirsi Kainulainen. The results help to understand how immune response affects the progression of prostate cancer and resistance to treatments. Observations on the effects of immune cells on the transformation capacity of cancer cells may open up new treatment opportunities for prostate cancer .

The study was carried out by Senior University Lecturer Sanna Pasonen-Seppänen and Research Director Kirsi Ketola at the University of Eastern Finland's Institute of Biomedicine. More information: Kirsi Kainulainen et al, Secreted factors from M1 macrophages drive prostate cancer stem cell plasticity by upregulating NANOG, SOX2 , and CD44 through NFκB-signaling, OncoImmunology (2024). DOI: 10.

1080/2162402X.2024.2393442.